帕尔哈提, 李 岚, 赵勤英, 姜述斌, 张宝简, 毛拉提, 马 俊. 使用替罗非班时泮托拉唑对非ST段抬高型急性冠脉综合征患者消化道保护作用的评[J]. 心脏杂志, 2012, 24(3): 366-369.
    引用本文: 帕尔哈提, 李 岚, 赵勤英, 姜述斌, 张宝简, 毛拉提, 马 俊. 使用替罗非班时泮托拉唑对非ST段抬高型急性冠脉综合征患者消化道保护作用的评[J]. 心脏杂志, 2012, 24(3): 366-369.
    Evaluation of the efficacy and safety of pantoprazole with tirofiban in protecting the alimentary canal of non-ST elevation acute coronary syndrome[J]. Chinese Heart Journal, 2012, 24(3): 366-369.
    Citation: Evaluation of the efficacy and safety of pantoprazole with tirofiban in protecting the alimentary canal of non-ST elevation acute coronary syndrome[J]. Chinese Heart Journal, 2012, 24(3): 366-369.

    使用替罗非班时泮托拉唑对非ST段抬高型急性冠脉综合征患者消化道保护作用的评

    Evaluation of the efficacy and safety of pantoprazole with tirofiban in protecting the alimentary canal of non-ST elevation acute coronary syndrome

    • 摘要: 目的:盐酸替罗非班、阿司匹林、氯吡格雷、低分子肝素(四联)联合使用治疗急性冠脉综合征(ACS)患者时,评价静脉注射泮托拉唑对消化道保护的疗效和安全性。方法: 选择住院ACS患者296例,随机分为试药组184例,对照组112例,所有患者均服用阿司匹林、氯吡格雷、低分子肝素和使用2~3 d盐酸替罗非班。在此基础上试药组患者静脉输注泮托拉唑40 mg/d,4~5 d,再服用泮托拉唑片剂40 mg/次,2次/d,连服8 d。结果: 试药组8 d内全因死亡、顽固性心绞痛、再次心肌梗死、急诊经皮冠状动脉介入治疗(PCI)数较对照组显著减少(P<0.05);试药组与对照组比较消化道出血发生率(2.2% vs. 12.5%)、TIMI小出血发生率(1.6% vs. 6.2%)和TIMI较小出血发生率(0.5% vs. 5.4%)明显降低(P<0.05)。结论: 在四联抗栓治疗ACS患者时,静脉注射和口服泮托拉唑可以减少8 d内消化道出血发生率,从而减少了8 d内患者死亡、顽固性心绞痛、再次心肌梗死、急诊PCI数,具有良好的消化道保护作用和安全性。

       

      Abstract: AIM:To evaluate the efficacy and safety of protecting the alimentary canal with pantoprazole when using the quadruple therapy: aspirin, clopidogrel, low molecular weight heparin (LMWH) and tirofiban hydrochloride in acute coronary syndrome (ACS). METHODS: Two hundred and ninety-six selected hospitalized patients with ACS were divided into observation group (n=184) and control group (n=112). Aspirin, clopidogrel, LMWH and 2-3 days of tirofiban were administered to all patients. On this basis, pantoprazole 40 mg i.v. was first administered by drip phleboclysis for 4-5 days and then changed to tablets (40 mg twice daily) for 8 days in the observation group. RESULTS: Occurrence of 8-day all-cause death, refractory angina pectoris, relapse myocardial infarction and emergency percutaneous coronary intervention (PCI) in the observation group was lower than that in the control group (P<0.05). The number of total hemorrhages, mild hemorrhages and midrange hemorrhages in the control group was higher than in the observation group (P<0.05). CONCLUSION: Intravenous injection and oral administration of pantoprazole decreased the 8-day rate of alimentary tract hemorrhage when using the quadruple anti-thrombosis therapy for ACS, thus decreasing the number of all-cause death for 8 days, intractable angina pectoris, intractable angina, relapse myocardial infarction and emergency PCI.

       

    /

    返回文章
    返回